SG11201803604UA - Methods and compositions for managing reproduction - Google Patents
Methods and compositions for managing reproductionInfo
- Publication number
- SG11201803604UA SG11201803604UA SG11201803604UA SG11201803604UA SG11201803604UA SG 11201803604U A SG11201803604U A SG 11201803604UA SG 11201803604U A SG11201803604U A SG 11201803604UA SG 11201803604U A SG11201803604U A SG 11201803604UA SG 11201803604U A SG11201803604U A SG 11201803604UA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- managing reproduction
- reproduction
- managing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2271—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562237017P | 2015-10-05 | 2015-10-05 | |
GBGB1517523.5A GB201517523D0 (en) | 2015-10-05 | 2015-10-05 | Methods and compositions for managing reproduction |
PCT/GB2016/053080 WO2017060685A1 (en) | 2015-10-05 | 2016-10-04 | Methods and compositions for managing reproduction |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201803604UA true SG11201803604UA (en) | 2018-05-30 |
Family
ID=54606069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201803604UA SG11201803604UA (en) | 2015-10-05 | 2016-10-04 | Methods and compositions for managing reproduction |
Country Status (9)
Country | Link |
---|---|
US (1) | US10588944B2 (en) |
EP (1) | EP3359127A1 (en) |
JP (1) | JP2018531940A (en) |
CN (1) | CN108289836A (en) |
AU (1) | AU2016334795A1 (en) |
CA (1) | CA3003668A1 (en) |
GB (2) | GB201517523D0 (en) |
SG (1) | SG11201803604UA (en) |
WO (1) | WO2017060685A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201314452D0 (en) | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
GB201501302D0 (en) | 2015-01-27 | 2015-03-11 | Ostara Biomedical Ltd | Embryo implantation |
CN107099501B (en) * | 2017-05-27 | 2022-04-05 | 广东华农大资产经营有限公司 | Method for inducing young primates to obtain gonad gametes and application |
CN107439411A (en) * | 2017-08-16 | 2017-12-08 | 杨旭升 | Method is exposed in a kind of ox heat based on activity monitoring |
CN110151354A (en) * | 2018-01-12 | 2019-08-23 | 塔里木大学 | One kind making the oestrus increased amount of method of Sheep Ovary advantage ovarian follicle |
CN109042515A (en) * | 2018-08-16 | 2018-12-21 | 阜阳师范学院 | Improve the attached method for planting quantity and nest litter size of body early embryo in goat body |
CN111249450A (en) * | 2020-01-20 | 2020-06-09 | 公安部南昌警犬基地 | Pharmaceutical composition for promoting dog estrus |
CN111616830A (en) * | 2020-07-03 | 2020-09-04 | 宁夏大学 | Novel ICR mouse superovulation method |
CN112715475B (en) * | 2020-12-28 | 2023-11-24 | 无锡珊瑚礁生物科技有限公司 | Method for improving farrowing rate of ferrets |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS563846B2 (en) * | 1972-10-12 | 1981-01-27 | ||
US4211769A (en) * | 1977-08-24 | 1980-07-08 | Takeda Chemical Industries, Ltd. | Preparations for vaginal administration |
AU4652596A (en) | 1995-01-09 | 1996-07-31 | Atrix Laboratories, Inc. | Liquid polymer delivery system |
AUPO550897A0 (en) | 1997-03-06 | 1997-03-27 | Luminis Pty Limited | Treatment and diagnosis of an infertility condition |
US7744916B2 (en) * | 1997-06-11 | 2010-06-29 | Umd, Inc. | Coated vaginal device for delivery of anti-migraine and anti-nausea drugs |
AU764479B2 (en) | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
US6258998B1 (en) | 1998-11-24 | 2001-07-10 | Infigen, Inc. | Method of cloning porcine animals |
CA2373073A1 (en) | 1999-05-07 | 2000-11-16 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
MX226123B (en) | 1999-09-17 | 2005-02-07 | Millennium Pharm Inc | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa. |
US6376515B2 (en) | 2000-02-29 | 2002-04-23 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor Xa |
US20090124690A1 (en) | 2000-04-03 | 2009-05-14 | Alberte Randall S | Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins |
WO2002000647A1 (en) | 2000-06-23 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
WO2003007955A2 (en) | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
US7173113B2 (en) | 2002-01-31 | 2007-02-06 | The Trustees Of Columbia University In The City Of New York | Long-acting hormone and growth factor compositions and uses thereof |
WO2004007472A1 (en) | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
AU2002951531A0 (en) | 2002-09-20 | 2002-10-03 | The University Of Adelaide | Treatment and diagnosis of an infertility condition by measuring or inhibiting interferon-y |
NZ571243A (en) | 2002-12-31 | 2010-04-30 | Altus Pharmaceuticals Inc | Complexes of protein crystals and ionic polymers comprising human growth hormone and protamine |
AR043633A1 (en) | 2003-03-20 | 2005-08-03 | Schering Corp | CANABINOID RECEIVERS LINKS |
AU2004233997C1 (en) * | 2003-04-29 | 2014-01-30 | Massachusetts Institiute Of Technology | Methods and devices for the sustained release of multiple drugs |
US20040248784A1 (en) * | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
US7323346B2 (en) | 2003-08-14 | 2008-01-29 | The General Hospital Corporation | Screening for gestational disorders |
PL1684782T3 (en) | 2003-10-03 | 2016-03-31 | Thorn Bioscience Llc | Process for the synchronization of ovulation for timed breeding without heat detection |
US8338373B2 (en) | 2003-10-24 | 2012-12-25 | Nora Therapeutics, Inc. | Method for reducing the risk of spontaneous abortion in a human female subject |
WO2005115456A2 (en) | 2004-05-28 | 2005-12-08 | President And Fellows Of Harvard College | METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY |
PL1753456T3 (en) | 2004-06-10 | 2017-01-31 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
JP5315611B2 (en) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | Compound having S1P receptor binding ability and use thereof |
CN100431546C (en) * | 2005-07-07 | 2008-11-12 | 天津市中意畜牧科技发展有限公司 | Progestational hormone composition, and its slow-release suppository device and preparation of said device |
WO2007011759A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
UY30117A1 (en) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | AMIS TRISUSTITUDED COMPOUND |
PE20071025A1 (en) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | TRISUSTITUTED AMINE COMPOUND |
US7790463B2 (en) | 2006-02-02 | 2010-09-07 | Yale University | Methods of determining whether a pregnant woman is at risk of developing preeclampsia |
WO2007113682A2 (en) | 2006-04-06 | 2007-10-11 | Novozymes Gropep Ltd | Tgf-beta pharmaceutical compositions |
ES2422597T3 (en) | 2006-11-28 | 2013-09-12 | Pictor Ltd | Test membrane and method of use thereof |
WO2008073670A2 (en) | 2006-12-08 | 2008-06-19 | Millennium Pharmaceuticals, Inc. | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor |
WO2008070902A1 (en) | 2006-12-11 | 2008-06-19 | Novozymes Biopharma Au Limited | Tgf-beta compositions for treating infertility |
US8192742B2 (en) | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
CN101874029A (en) | 2007-07-13 | 2010-10-27 | 艾德克斯药品股份有限公司 | Pyrazole derivatives as metabotropic glutamate receptor modulators |
WO2009010871A2 (en) | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Pyrazole derivatives as antagonists of adenosine a3 receptor |
JP4834699B2 (en) | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | Pharmaceutical composition |
AU2008293038B2 (en) | 2007-08-29 | 2013-08-29 | Mirati Therapeutics, Inc. | Inhibitors of protein tyrosine kinase activity |
US8003324B2 (en) | 2007-10-18 | 2011-08-23 | U.S. Department Of Veterans Affairs | Modulation of sodium channels by nicotinamide adenine dinucleotide |
GB0806281D0 (en) | 2008-04-07 | 2008-05-14 | Univ Leeds | Markers of Oocyte viability |
WO2009139784A1 (en) | 2008-05-13 | 2009-11-19 | Nora Therapeutics, Inc. | Human g-csf analogs and methods of making and using thereof |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
AR074760A1 (en) | 2008-12-18 | 2011-02-09 | Metabolex Inc | GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME. |
WO2010126528A1 (en) * | 2009-05-01 | 2010-11-04 | Nora Therapeutics, Inc. | Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination |
JP5722885B2 (en) | 2009-06-18 | 2015-05-27 | セレクティス アーベー | 3D culture system for growth and differentiation of human pluripotent stem (hPS) cells |
KR20120092567A (en) | 2009-08-05 | 2012-08-21 | 벌시테크 리미티드 | Antiviral compounds and methods of making and using thereof cross reference to related applications |
US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
US8882748B2 (en) * | 2009-10-08 | 2014-11-11 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including chemical permeation enhancers |
AU2011256088B2 (en) | 2010-05-20 | 2015-03-26 | University Of Saskatchewan | Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal |
ES2526124T3 (en) | 2010-06-16 | 2015-01-07 | Cymabay Therapeutics, Inc. | GPR120 receptor agonists and their uses |
WO2012079032A2 (en) | 2010-12-09 | 2012-06-14 | Trana Discovery, Inc. | Compositions and methods of treating drug-resistant retroviral infections |
CN103298460B (en) | 2010-12-14 | 2016-06-01 | 电泳有限公司 | Casein kinase 1 �� (CK1 ��) inhibitor |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
ITTO20111183A1 (en) | 2011-12-21 | 2013-06-22 | Univ Degli Studi Torino | CONDITIONAL MEANS OBTAINED FROM PLACENTARY STEM CELLS AND ITS USE IN THE THERAPEUTIC TREATMENT OF PREECLAMPSIA |
US9005108B2 (en) * | 2012-09-27 | 2015-04-14 | Palo Alto Research Center Incorporated | Multiple reservoir drug delivery device and methods |
ITMI20122063A1 (en) | 2012-12-03 | 2014-06-04 | Marco Sbracia | GM-CSF FOR THE USE IN THE PREVENTION OF THE SPONTANEOUS ABORTION AND THE FAILURE OF THE EMBRYO SYSTEM |
GB201314452D0 (en) * | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
EP3074031A4 (en) * | 2013-11-27 | 2017-08-09 | JBS United Animal Health II LLC | Method and composition for synchronizing time of insemination in gilts |
GB201501302D0 (en) | 2015-01-27 | 2015-03-11 | Ostara Biomedical Ltd | Embryo implantation |
-
2015
- 2015-10-05 GB GBGB1517523.5A patent/GB201517523D0/en not_active Ceased
-
2016
- 2016-10-04 CN CN201680069611.9A patent/CN108289836A/en active Pending
- 2016-10-04 SG SG11201803604UA patent/SG11201803604UA/en unknown
- 2016-10-04 JP JP2018517614A patent/JP2018531940A/en active Pending
- 2016-10-04 AU AU2016334795A patent/AU2016334795A1/en not_active Abandoned
- 2016-10-04 GB GB1616851.0A patent/GB2548649A/en not_active Withdrawn
- 2016-10-04 CA CA3003668A patent/CA3003668A1/en not_active Abandoned
- 2016-10-04 WO PCT/GB2016/053080 patent/WO2017060685A1/en active Application Filing
- 2016-10-04 US US15/285,240 patent/US10588944B2/en not_active Expired - Fee Related
- 2016-10-04 EP EP16781845.9A patent/EP3359127A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
GB201517523D0 (en) | 2015-11-18 |
JP2018531940A (en) | 2018-11-01 |
CN108289836A (en) | 2018-07-17 |
EP3359127A1 (en) | 2018-08-15 |
US20170095536A1 (en) | 2017-04-06 |
US10588944B2 (en) | 2020-03-17 |
CA3003668A1 (en) | 2017-04-13 |
GB201616851D0 (en) | 2016-11-16 |
AU2016334795A1 (en) | 2018-05-24 |
WO2017060685A1 (en) | 2017-04-13 |
GB2548649A (en) | 2017-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1257295A1 (en) | Compositions and methods for immunooncology | |
HK1256817A1 (en) | Compositions and methods for genome editing | |
HK1252358A1 (en) | Methods and compositions for determining ploidy | |
HK1243333A1 (en) | Methods and compositions for modified t cells | |
ZA201804070B (en) | Eif4-a-inhibiting compounds and methods related thereto | |
EP3328377A4 (en) | Compositions and methods for immuno-oncology therapies | |
EP3379935A4 (en) | Methods and compositions for reducing vancomycin-resistantenterococci | |
GB2546350B (en) | Compositions and methods | |
GB2535253B (en) | Compositions and methods | |
HK1251610A1 (en) | Compositions and methods for inhibiting factor d | |
GB201616851D0 (en) | Methods and compositions for managing reproduction | |
GB201718876D0 (en) | Antithrombin-heparin compositions and methods | |
IL258292A (en) | Methods and compositions for reducing metastases | |
IL268684A (en) | Compositions and methods for immunooncology | |
IL246879A0 (en) | Apilimod compositions and methods for using same | |
GB201417828D0 (en) | New methods and compositions | |
HK1245158A1 (en) | Apilimod compositions and methods for using same | |
IL274524A (en) | Compositions and methods for aquaculturing | |
HK1246193A1 (en) | Methods and compositions for improved cognition | |
HK1254550A1 (en) | Compositions and methods for inhibiting beta-lactamase | |
PT3113774T (en) | Compositions of grapiprant and methods for using the same | |
GB201512996D0 (en) | Compositions and methods | |
PT3160263T (en) | Compositions and methods for preventing infections | |
GB201514413D0 (en) | Compositions and methods | |
GB201402915D0 (en) | Compositions and methods |